Abstract 2975: Development of a probody drug conjugate (PDC) targeting CD71 for the treatment of solid tumors and lymphomas

Shweta Singh,A. DuPage,A. Y. Weaver,J. Sagert,Clayton White,Michael Krimm,Yuanhui Huang,L. Diep,K. Tipton,Shouchun Liu,J. Richardson,W. Kavanaugh,J. Terrett,Luc R Desnoyers

Published 2016 in Cancer Research

ABSTRACT

No abstract is available for this paper.

PUBLICATION RECORD

Publication year
2016
Venue
Cancer Research
Publication date
2016-07-15
Fields of study
Medicine, Chemistry
Identifiers
DOI 10.1158/1538-7445.AM2016-2975
External record
Open on Semantic Scholar
Source metadata
Semantic Scholar

CITATION MAP

EXTRACTION MAP

CLAIMS

No claims are published for this paper.

CONCEPTS

No concepts are published for this paper.

REFERENCES

No references are available for this paper.

CITED BY

Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences
2022influential citation
Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity
2021cites this paper
Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody
2020cites this paper
Antibody prodrugs for cancer
2019cites this paper
Assessing localized conformational stability of antibody-drug conjugate by protein conformation assay.
2019cites this paper